After a brief market exit in November 2022, GSK appears to be giving its multiple myeloma treatment Blenrep a second chance, with company executives touting its “multi-blockbuster” potential in a virtual oncology-focused investor event on Monday.

MRI scan, brain

Neurocrine Biosciences on Thursday announced that two of its candidates—from separate partnerships with Xenon Pharmaceuticals and Takeda—failed their respective Phase II studies in focal onset seizures and major depressive disorder.


September 24 is World Cancer Research Day, dedicated to supporting the research and innovations that improve outcomes for cancer patients across the globe. So far this year, the FDA has approved ten novel anticancer therapies, for breast cancer, multiple myeloma, acute myeloid leukemia and more. 

Wegovy, Novo Nordisk

Novo Nordisk has hired U.S. private contract manufacturer PCI Pharma Services to handle assembly and packaging of Wegovy, a source familiar with the matter said, as it races to boost output of the weight-loss drug to meet demand.

IPG Health

The new multidisciplinary offering addresses industry need for more inclusive clinical trials and product development.

Tonix Pharmaceuticals Holding Corp. said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19.

An experimental blood test that detected Parkinson’s disease in a preliminary study could become the first specific tool for diagnosing the devastating neurodegenerative condition, researchers said on Wednesday.

In the Phase III INNOVATE-3 trial, Novocure’s investigational ovarian cancer therapy Tumor Treating Fields was unable to significantly improve overall survival, the company announced Monday.

A first-in-human Phase I trial showed that Eli Lilly’s investigational oral lipoprotein(a) inhibitor muvalaplin was safe and could elicit sharp reductions in concentrations of cholesterol formation.


Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker’s shares even though more data will be needed to confirm the treatment’s efficacy.